Abstract
Pregabalin (PGB) and gabapentin (GBP), both gabapentinoids, are established add-on therapy for focal onset epileptic seizures. Up to 10% of people with refractory focal epilepsy may become seizure-free with PGB as add-on therapy. PGB has a higher response rate but also higher adverse effects rate than GBP. The efficacy of PGB and GBP appears to be independent of the severity of the epilepsy. PGB and GBP are relatively safe drugs; their side effects are usually mild (dizziness, ataxia, weight gain, asthenia, and somnolence are the most frequent). The long-term retention rate, a composite of efficacy and tolerability, is, however, not impressive when compared to other antiepileptic drugs.
This is a preview of subscription content, log in via an institution to check access.
References
Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, Garofalo E. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia. 1999;40(8):1147–54.
Baulac M, Leon T, O’Brien T, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial onset seizures. Epilepsy Research. 2010;91(1):10–9.
Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64:475–80.
Crettenand M, Rossetti AO, Buclin T, Winterfeld U. [Use of antiepileptic drugs during breastfeeding: what do we tell the mother?] Nervenarzt. 2018;89(8):913–21.
Fisher RS, Sachdeo RC, Pellock J, Penovich PE, Mahnus L, Bernstein P. Rapid Initiation of gabapentin: a randomised control trial. Neurology. 2001;56:743–8.
French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology. 2003;60:1631–7.
Hamandi K, Sander JW. Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure. 2006;15(2):73–8.
Iacobucci G. UK government to reclassify pregabalin and gabapentin after rise in deaths. BMJ. 2017;358:j4441.
Langan Y, Duncan JS, Sander JW. An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. Eur Neurol. 1999;41(2):111–3.
Mäkinen J, Peltola J, Raitanen J, Alapirtti T, Rainesalo S. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017;264(7):1345–53.
Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR, SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.
Panebianco M, Al-Bachari S, Weston J, Hutton JL, Marson AG. Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2018;10:CD001415.
Panebianco M, Bresnahan R, Hemming K, Marson AG. Pregabalin add-on for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2019;7:CD005612. https://doi.org/10.1002/14651858.CD005612.pub4.
Patorno E, Bateman BT, Huybrechts KF, MacDonald SC, Cohen JM, Desai RJ, Panchaud A, Mogun H, Pennell PB, Hernandez-Diaz S. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017;88(21):2020–5.
Sethi A, Chandra D, Puir V, Mallika V. Gabapentin and lamotrigine in Indian patients of partial epilepsy refractory to carbamazepine. Neurology India. 2002;50(3):359–63.
Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, Ziemann A, Isojarvi J. Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: meta-analysis of pivotal trials. Epilepsy Res. 2018;143:120–9.
UK Gabapentin. The UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet. 1990;335(8698):1114–7.
US Gabapentin. The US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a doubleblind, placebo-controlled, parallel-group study. Neurology. 1993;43(11):2292–8.
Yuen AW, Singh R, Bell GS, Bhattacharjee A, Neligan A, Heaney DC, Duncan JS, Sander JW. The long-term retention of pregabalin in a large cohort of patients with epilepsy at a tertiary referral centre. Epilepsy Res. 2009;87(2-3):120–3.
Zhao T, Feng X, Liu J, Gao J, Zhou C. Evaluate the efficacy and safety of anti-epileptic medications for partial seizures of epilepsy: a network meta-analysis. J Cell Biochem. 2017;118(9):2850–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Agró, L., Demurtas, R., Sander, J.W. (2020). Anticonvulsant Agents: Gabapentin and Pregabalin. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_299-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_299-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine